HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetic Ingredient Use Under Feinstein Bill; Where Does CIR Come In?

This article was originally published in The Rose Sheet

Executive Summary

Whereas previous industry-backed legislation would have made final Cosmetic Ingredient Review safety determinations de facto FDA requirements unless the agency concluded differently, CIR would play a less conspicuous role in national cosmetics oversight under the proposed Personal Care Products Safety Act. Meanwhile, manufacturers would be required to file ingredient statements with FDA and attest to product safety, with opportunities for FDA to rebut their assertions and even suspend their distribution activities.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts